Tumorbiologie und moderne Labordiagnostik

  • M. Taron
  • C. Sàrries
  • J.L. Ramírez
  • R. Rossell


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aitman TJ (2001) DNA microarrays in medical practice. Br Med J 323: 611–615Google Scholar
  2. Balaña C, Ramirez JL, Taron M et al. (2003) MGMT methylation in serum and tumor DNA predicts response to BCNU but not to temozolamide plus cisplatin in glioblastoma multiform. Clin Cancer Res 9(4): 1461–1468PubMedGoogle Scholar
  3. Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25: 169–193CrossRefPubMedGoogle Scholar
  4. Chen X, Sullivan PF (2003) Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmocol J 3: 77–96Google Scholar
  5. Dabholkar M, Vionnet J, Bostick-Bruton F et al (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703–708PubMedGoogle Scholar
  6. Duggan DJ, Bittner M, Chen Y et al (1999) Expression profiling using cDNA microarrays. Nat Genet 21(Suppl 1): 10–14PubMedGoogle Scholar
  7. Esteller M, Garcia-Foncillas J, Andion et al. (2000) Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350–1354CrossRefPubMedGoogle Scholar
  8. Ford BN, Ruttan CC, Kyle VL et al. (2000) Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis 21: 1977–1981PubMedGoogle Scholar
  9. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 20: 2042–2054Google Scholar
  10. Hu G, Modrek B, Stensland HMFR et al. (2002) Efficient dis-covery of single-nucleotide polymorphisms in coding regions of human genes. Pharmacogenomics J 2: 236–242CrossRefPubMedGoogle Scholar
  11. Isla D, Sarries C, Rosell R et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel/cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15:1194–1203CrossRefPubMedGoogle Scholar
  12. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415–428CrossRefPubMedGoogle Scholar
  13. Krug L Azzoli CG, Kris MG, et al (2003) 10-Propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res 9: 2072–2078PubMedGoogle Scholar
  14. Lander ES (1999) Array as a hope. Nat Genet 21(Suppl 1): 3–4PubMedGoogle Scholar
  15. Lehmann U, Kreipe H (2001) Real Time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded bio-psies. Methods 25: 409–418CrossRefPubMedGoogle Scholar
  16. Li Q, Yu JJ, Mu C. et al. (2000) Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645–652PubMedGoogle Scholar
  17. Lord RVN, Brabender J, Gandara D et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res 8: 2286–2291PubMedGoogle Scholar
  18. Metzger R, Leichman G, Danenberg KD et al. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309–316PubMedGoogle Scholar
  19. Ntzani E, Ioannidis JPA (2003) Predictive ability of microarrays for cancer outcomes and correlates: an empirical assess-ment. The Lancet 362: 1439–1444CrossRefGoogle Scholar
  20. Ramírez JL, Sàrries C, López de Castro P et al. (2003) Methylation patterns and k-ras mutations in tumors and paired serum of resected NSCLC patients. Cancer Letters 193(2): 207–216PubMedGoogle Scholar
  21. Ring HZ, Kroetz DL (2002) Candidate gene approach for pharmacogenomic studies. Pharmacogenomics 3(1): 47–56CrossRefPubMedGoogle Scholar
  22. Roden DM, George AL (2002) The genetic basis of variability in drug responses. Nature Rev 1: 37–44Google Scholar
  23. Rosell R, Crino L, Danenberg K et al. (2003a) Targeted therapy in combination with gemcitabine in NSCLC. Sem Oncol 30(4): 19–25Google Scholar
  24. Rosell R, Scagliotti G, Danenberg KD et al. (2003b) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548–3553CrossRefPubMedGoogle Scholar
  25. Rosell R, Danenberg KD, Alberola V et al. (2004) Ribonucleotide reductase mRNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small-cell lung cancer patients. Clin Cancer Res 15: 1318–1325Google Scholar
  26. Sarries C, Haura EB, Roig B et al. (2002) Pharmacogenomic strategies for developing customized chemotherapy in nonsmall cell lung cancer. Pharmacogenomics 3(6): 1–18CrossRefGoogle Scholar
  27. Specht K, Richter T, Müller M et al. (2001) Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Path 158: 419–429PubMedGoogle Scholar
  28. Twyman RM, Primrose SB (2003) Techniques patents for SNP genotyping. Pharmacogenomics 4(1): 67–79CrossRefPubMedGoogle Scholar
  29. Watters JW, McLeod HL (2003) Cancer pharmagenomics: current and future applications. Biochim Biophys Acta 1603: 99–111PubMedGoogle Scholar
  30. Winegarden N (2003) Microarrays in cancer: moving from hype to clinical reality. The Lancet 362: 1428CrossRefGoogle Scholar
  31. Yu JJ, Mu C, Lee KB, et al (1997) A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 382: 13–20PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2005

Authors and Affiliations

  • M. Taron
    • 1
  • C. Sàrries
    • 1
  • J.L. Ramírez
    • 1
  • R. Rossell
    • 1
  1. 1.Medical Oncology Service Institut Català d’OncologiaHospital Germans Trias i PujolBadalona (Barcelona)Spain

Personalised recommendations